Skip to main content

IgM-associated Polyneuropathy

​Updated 20 June 2007 

Five percent to 10% of patients with lymphoma and an associated IgM monoclonal protein (usually lymphoplasmacytic lymphoma, also known as Waldenstrom’s macroglobulinemia) also develop anti-MAG (myelin-associated glycoprotein) antibodies and polyneuropathy. Such patients should be treated with standard chemotherapy for advanced stage indolent lymphoma (see Table 3.1) and approximately 50% will experience improvement in the neuropathy. However, some patients with IgM monoclonal protein and anti-MAG antibodies develop polyneuropathy without histologic evidence of underlying lymphoma despite the fact that the presence of the monoclonal IgM implies the existence of an underlying monoclone of malignant B-cells. Evidence concerning the usefulness of anti-lymphoma treatment in such patients is not definitive, with anecdotal series documenting improvement and the only randomized trial under-powered and not focused on the most relevant endpoints.

The BCCA Lymphoid Cancer Tumor Group recommends that patients with IgM-associated polyneuropathy be co-managed by an oncologist/hematologist and a neurologist experienced in the diagnosis and treatment of polyneuropathy as shown below. Such patients should undergo a careful search for underlying lymphoma, including a bone marrow biopsy, and all other conditions such as nutritional deficiency or spinal stenosis should be eliminated as possible causes before employing these treatment recommendations.

Clinical setting: IgM-associated polyneuropathy and histologically proven coincident indolent lymphoma

Recommended treatment: As for advanced stage indolent lymphoma, see Treatment section above 

Clinical setting: IgM-associated polyneuropathy in the absence of histologically proven coincident indolent lymphoma 

Recommended treatment: Single agent rituximab 375 mg/m2 IV weekly for 4 weeks (LYRITUX, requires Compassionate Access Program (CAP) approval)

SOURCE: IgM-associated Polyneuropathy ( )
Page printed: . Unofficial document if printed. Please refer to SOURCE for latest information.

Copyright © BC Cancer. All Rights Reserved.

    Copyright © 2021 Provincial Health Services Authority